NeuroBo Submits IND Application For Phase 1 Clinical Trial Of DA-1726; Stock Up In Pre-market

NeuroBo Pharmaceuticals, Inc. (NRBO), a clinical-stage biotechnology company, Thursday said it has submitted Investigational New Drug or IND application to FDA, regarding Phase 1 clinical trial of DA-1726 for the treatment of obesity.

Related Keywords

,Nasdaq ,Neurobo Pharmaceuticals Inc ,Neurobo Pharmaceuticals ,Investigational New Drug ,Biopharmaceutical ,Nd Application ,Eurobo ,A 1726 ,